RFK Jr. halts $500 million for mRNA vaccine research
RFK Jr., the former CEO of Johnson & Johnson and a prominent figure in the fight against COVID-19, has announced a decision to halt $500 million worth of research projects related to mRNA-based vaccines. The move stems from concerns about economic and public health priorities, with some experts suggesting that continued funding for these vaccines may not be sustainable in the long run.RFK's legacy as a pioneer in mRNA technology is tied closely to this decision, as his work laid the groundwork for the development of early mRNA vaccines. His advocacy for innovation in addressing the pandemic has been influential, and this announcement reflects a broader shift toward prioritizing public health outcomes over short-term financial gains.
------
